Clinical Trials | December 09, 2025
Pharvaris’ deucrictibant shows rapid relief for hereditary angioedema in pivotal Phase 3 trial
The study met its primary endpoint and all 11 secondary efficacy endpoints
The study met its primary endpoint and all 11 secondary efficacy endpoints
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
This is the 166th ANDA out of Eugia Pharma Speciality Group facilities
Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support
Subscribe To Our Newsletter & Stay Updated
